Protalix BioTherapeutics Inc. – Filings and Transcripts

NYSE American: PLX
Share price (3/24/26): $2.07
Market cap (3/24/26): $167 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

ended 03/31/25 Q1

ended 12/31/24 FY 2024

Prospectuses and Registrations Filter

Prospectus supplement for primary offering

Shelf registration – amended

Shelf registration

Prospectus supplement for primary offering

Registration of securities for employees

Ownership Filter

MAK Capital Fund LP

Bar-Shalev Amos

News Filter

Reports Fiscal Year 2025 Financial and Business Results

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio®

Investor Presentation

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (Pegunigalsidase Alfa) in the EU

Letter to Stockholders

Proxies Filter

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Other Filter

Notice of effectiveness

Correspondence with the SEC

Scanned paper annual report submission

Letter from the SEC

Scanned paper annual report submission